Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200 Day Moving Average of $4.64

Puma Biotechnology, Inc. (NASDAQ:PBYI) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.64 and traded as high as $4.97. Puma Biotechnology shares last traded at $4.96, with a volume of 319,771 shares traded.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PBYI shares. StockNews.com raised Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Friday.

Puma Biotechnology Price Performance

The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.50 and a current ratio of 1.57. The company has a market capitalization of $234.30 million, a P/E ratio of 14.73, a P/E/G ratio of 2.82 and a beta of 1.31. The firm’s fifty day moving average is $5.35 and its 200 day moving average is $4.66.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.07). Puma Biotechnology had a net margin of 6.79% and a return on equity of 37.69%. The business had revenue of $72.20 million for the quarter, compared to analysts’ expectations of $73.22 million. As a group, analysts predict that Puma Biotechnology, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Puma Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the business. Citigroup Inc. bought a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $262,000. Assenagon Asset Management S.A. increased its holdings in Puma Biotechnology by 23.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 15,897 shares during the period. Ritholtz Wealth Management bought a new stake in Puma Biotechnology during the 4th quarter valued at $66,000. GSA Capital Partners LLP lifted its holdings in shares of Puma Biotechnology by 143.8% in the 3rd quarter. GSA Capital Partners LLP now owns 279,629 shares of the biopharmaceutical company’s stock worth $735,000 after buying an additional 164,931 shares during the period. Finally, Jump Financial LLC grew its position in shares of Puma Biotechnology by 26.6% during the 3rd quarter. Jump Financial LLC now owns 24,690 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 5,190 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.